Boston, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leader in hybrid care enablement, announced that the company will participate in several investor conferences in September.
Ido Schoenberg, M.D., Amwell’s chairman and CEO, and Robert Shepardson, Amwell’s CFO, will participate in the following conferences via fireside chat and one-on-one meetings held throughout the day:
September 4, Morgan Stanley 22nd Annual Global Healthcare Conference in New York City; fireside chat at 1:50 p.m. ET.
September 5, Wells Fargo Healthcare Conference in Boston (one-on-one meetings only).
On September 10, Mr. Shepardson will participate in one-on-one investor meetings at the Baird Healthcare Conference in New York City, as well as a panel discussion during the TD Cowen 9th’s Annual FutureHealth Conference held at 2:20 p.m.ET at One Vanderbilt in New York City.
An audio webcast of the Morgan Stanley fireside chat and the TD Cowen panel will be available at investors.amwell.com.
About Amwell
Amwell is a leading hybrid care delivery enablement platform in the United States and globally, connecting and enabling providers, payers, patients, and innovators to deliver greater access to more affordable, higher quality care. Amwell believes that hybrid care delivery will transform healthcare. We offer a single, comprehensive platform to support all digital health needs from urgent to acute and post-acute care, as well as chronic care management and healthy living. With nearly two decades of experience, Amwell powers the digital care of more than 50 health plans, which collectively represent more than 100 million covered lives, and many of the nation’s largest health systems. For more information, please visit https://business.amwell.com/.
©2024 American Well Corporation. All rights reserved. Amwell®, SilverCloud®, Amwell ConvergeTM, CarepointTM and the Amwell Logo are registered trademarks or trademarks of American Well Corporation.
Last Trade: | US$6.98 |
Daily Change: | -0.04 -0.57 |
Daily Volume: | 53,414 |
Market Cap: | US$95.420M |
February 12, 2025 January 15, 2025 December 18, 2024 October 30, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load